Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08JIP
|
|||
| Former ID |
DNCL002518
|
|||
| Drug Name |
Rintatolimod
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 3 | [1] | |
| Company |
Hemispherx Biopharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02151448) alphaDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One. 2012;7(3):e31334. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.